David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
|Videos|March 28, 2011
Dr. Petrylak Explains Prostate Cancer Clinical Trial Difficulties
Author(s)Daniel P. Petrylak, MD
Daniel P. Petrylak, MD, from Columbia University Medical Center Explains the Difficulties Facing During Prostate Cancer Clinical Trials
Advertisement
Daniel P. Petrylak, MD, Professor of Medicine, Program Director of the Genitourinary Oncology Section in the Division of Hematology/Oncology and Co-Leader, Prostate Cancer in the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center Explains the Difficulties Facing During Prostate Cancer Clinical Trials
Advertisement
Related to this article
Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.
Lutetium Lu 177 vipivotide tetraxetan showed a median overall survival of 13.1 months in the French PSMA-REACH mCRPC cohort.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The top 5 OncLive TV videos of the week cover insights in endometrial cancer, mCRPC, germ cell tumors, melanoma, and HNSCC.
Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.
The FDA approved talazoparib plus enzalutamide for HRR-positive, metastatic androgen pathway modulation–naive or -sensitive prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILs
2
EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma
3
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
4
Zanidatamab, CLDN18.2-Directed ADCs, Ivonescimab, and KRAS Inhibitor Data Headline Key GI Cancer Findings From ESMO 2026
5